3'-chloro-4-phenyl-1'-(4-trifluoromethoxybenzyl)-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-one | 1127498-13-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3'-chloro-4-phenyl-1'-(4-trifluoromethoxybenzyl)-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-one
• 英文别名: 3-Chloro-4-(4-phenylpiperidin-1-yl)-1-[[4-(trifluoromethoxy)phenyl]methyl]pyridin-2-one
• CAS: 1127498-13-8
• 化学式: C₂₄H₂₂ClF₃N₂O₂
• 分子量: 462.899
• InChiKey: QMXOEWYJDSCILA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-苯基哌啶 、 4-bromo-3-chloro-1-(4-trifluoromethoxy-benzyl)-1H-pyridin-2-one 在 2-(2'-di-tert-butylphosphine)biphenylpalladium(II) acetate potassium phosphate 作用下， 以 1,4-二氧六环 为溶剂， 反应 35.0h， 以31%的产率得到3'-chloro-4-phenyl-1'-(4-trifluoromethoxybenzyl)-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-one
  参考文献：
  名称：

  [EN] 1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-[1, 4'] BIPYRIDINYL-2'-ONES
  [FR] 4-PHÉNYL-3,4,5,6-TÉTRAHYDRO-2H,1'H-[1, 4'] BIPYRIDINYL-2'-ONES 1', 3'-DISUSBSTITUÉES

  摘要：

  本发明涉及新型化合物，特别是根据式（I）中定义的新型吡啶酮衍生物，其中所有基团均如申请和权利要求中所定义。根据本发明的化合物是代谢型受体亚型2（'mGluR2'）的阳性变构调节剂，用于治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病，以及mGluR2代谢型受体亚型涉及的疾病。具体来说，这些疾病是来自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的选择性疾病。本发明还涉及制备这种化合物和组合物的药物组合物和方法，以及利用这种化合物预防和治疗mGluR2涉及的疾病。

  公开号：

  WO2009033704A1

文献信息

• [EN] COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE<br/>[FR] COMBINAISONS COMPRENANT DES MODULATEURS ALLOSTÉRIQUES POSITIFS OU DES AGONISTES ORTHOSTÉRIQUES DE SOUS-TYPE 2 DE RÉCEPTEUR GLUTAMATERGIQUE MÉTABOTROPE, ET LEUR UTILISATION
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015110435A1

  公开（公告）日：2015-07-30

  The present invention relates to combinations comprising a positive allosteric modulator ("PAM") of metabotropic glutamatergic receptor subtype 2 ("mGluR2") or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A ("SV2A") ligand.

  本发明涉及组合物，包括一种代谢型谷氨酸受体亚型2（"mGluR2"）的正向变构调节剂（"PAM"）或其药用可接受盐或溶剂，或一种代谢型谷氨酸受体亚型2的正交合激动剂化合物或其药用可接受盐或溶剂，以及突触囊泡蛋白2A（"SV2A"）配体。
• 1,3-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1 H-1,4 BIPYRIDINYL-2-ONES
  申请人：Cid-Nunez Jose Maria

  公开号：US20100240688A1

  公开（公告）日：2010-09-23

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及一种新型化合物，特别是公式（I）中所示的新型吡啶酮衍生物，其中所有基团均如申请和权利要求中所定义。本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体mGluR2亚型的疾病。特别是，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病中选择的。本发明还涉及制备这种化合物和组合物的制药组合物和制备过程，以及利用这种化合物预防和治疗涉及mGluR2的这些疾病的用途。
• 1',3'-DISUBSTITUTED-4-PHENY-3,4,5,6-TETRAHYDRO-2H,1'H-[1,4']BIPYRIDINYL-2'-ONES
  申请人：CID-NUNEZ Jose Maria

  公开号：US20130196992A1

  公开（公告）日：2013-08-01

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是公式（I）中所示的新型吡啶酮衍生物，其中所有基团均如本申请和权利要求中所定义。本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍和mGluR2代谢型受体有关的神经和精神障碍以及相关疾病。特别地，这些疾病是选择自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的群体。本发明还涉及制备这种化合物和组合物的制药组合物和过程，以及利用这种化合物预防和治疗涉及mGluR2的这些疾病的用途。
• 1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1'H-[1,4']BIPYRIDINYL-2'-ONES
  申请人：CID-NUNEZ Jose Maria

  公开号：US20130197019A1

  公开（公告）日：2013-08-01

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是根据公式（I）定义的新型吡啶酮衍生物，其中所有基团如本申请和权利要求中所定义。本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍和mGluR2代谢型受体有关的神经和精神障碍以及这些疾病。特别是，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫的中枢神经系统疾病中选择的。本发明还涉及制备这种化合物和组合物的药物组合物和制备过程，以及利用这种化合物预防和治疗涉及mGluR2的这些疾病的用途。
• 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20150336930A1

  公开（公告）日：2015-11-26

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是根据式（I）定义的新型吡啶酮衍生物，其中所有基团如申请和权利要求中所定义。本发明的化合物是代谢型受体亚型2（“mGluR2”）的阳性变构调节剂，对于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及mGluR2代谢型受体参与的疾病非常有用。特别是，这些疾病是选择自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的一组。本发明还涉及制备这种化合物和组合物的制药组合物和制备过程，以及将这种化合物用于预防和治疗涉及mGluR2的这些疾病的用途。